The incidence of recurrent Clostridioides difficile infection was lower among at-risk patients on antibiotics for other ...

Rimegepant 75 mg for 52 weeks is well tolerated, with no liver safety signals and a sustained reduction in monthly migraine days, a new extension study shows.

The approval was supported by data from the randomized, double-blind, placebo-controlled, event-driven phase 3 FINEARTS-HF study.

Fractyl Health offers a high-risk, high-reward setup with a near-term binary catalyst in the REMAIN-1 cohort data expected Q3 ...

Tocilizumab significantly reduced 28-day mortality and length of ICU stay in patients with severe COVID-19 pneumonia and low S-spike nAb titers.

Patients with knee osteoarthritis who received metformin demonstrated significant reductions in knee pain and increased ...

Eli Lilly is advancing its Phase 2 clinical trial to test LY3841136 for weight management in obese and overweight adults.

Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that all the 28 participants have recently been dosed in the randomized, double-blind, placebo-controlled study (ASC47-103 study, NCT06972992) ...

BiomX Inc. (AMEX:PHGE) saw its stock jump 60% after announcing the commencement of patient dosing in its Phase 2b clinical ...

Turn Therapeutics today announced the initiation of a randomized, double-blind, vehicle-controlled clinical trial evaluating its topical GX-03 formulation -- previously used in the company's advanced ...

Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in ...